Zacks.com on MSN1h
Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLCMerck MRK announced that the FDA has granted breakthrough therapy designation (BTD) to sacituzumab tirumotecan (sac-TMT) for ...
Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...
A medical expert discusses how Lambert-Eaton myasthenic syndrome is closely linked to small cell lung cancer, the challenges ...
Guggenheim analyst Michael Schmidt raised the firm’s price target on Revolution Medicines (RVMD) to $87 from $82 and keeps a ...
Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell ...
Precision medicine in the context of lung cancer represents a transformative approach that integrates prevention, diagnosis, and treatment tailored to individual patient differences. This field ...
The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed by Cancer Research UK-funded scientists from UCL and The Francis Crick ...
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...
BofA Securities, TD Cowen, Stifel, Cantor and William Blair are acting as joint book-running managers for the offering. Wedbush PacGrow, LifeSci Capital, BTIG and Jones are acting as co-managers for ...
A study from the University of Michigan Health Rogel Cancer Center may have—at last—cracked the cold case of immunotherapy ...
A study from the University of Michigan Health Rogel Cancer Center may have, at last, cracked the cold case of immunotherapy resistance.The research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback